PPIDT00109
Drug Information
| Name | Abatacept |
|---|---|
| Sequence | MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB01281 |
| Type | biotech |
| Indication | Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and in patients ≥2 years of age for the treatment of active psoriatic arthritis.[L48811] In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.[L20504] Abatacept is also indicated for the prophylaxis of acute graft-versus-host disease, in combination with [methotrexate] and a calcineurin inhibitor such as [tacrolimus], in patients two years of age and older who are undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.[L20504] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Other |
262.500 mg
|
| Injection, powder, for solution | Intravenous |
250 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
250 mg/15mL
|
| Injection, solution | Parenteral; Subcutaneous |
125 MG
|
| Injection, solution | Parenteral; Subcutaneous |
50 MG
|
| Injection, solution | Parenteral; Subcutaneous |
87.5 MG
|
| Injection, solution | Subcutaneous |
125 mg/1mL
|
| Injection, solution | Subcutaneous |
125 mg
|
| Injection, solution | Subcutaneous |
50 mg/0.4mL
|
| Injection, solution | Subcutaneous |
50 mg
|
| Injection, solution | Subcutaneous |
87.5 mg/0.7mL
|
| Injection, solution | Subcutaneous |
87.5 mg
|
| Powder | — |
250 mg/1vial
|
| Powder, for solution | Intravenous |
250 mg / vial
|
| Solution | Subcutaneous |
125 mg / mL
|
| Injection, powder, lyophilized, for solution | Intravenous |
26250000 mg
|
| Powder, for solution | Intravenous |
250 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
262.5 MG
|
| Injection | Subcutaneous |
125 mg
|
| Injection, solution | — |
125 mg
|
| Solution | Subcutaneous |
12500000 mg
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P33681 | CD80 | T-lymphocyte activation antigen CD80 | Homo sapiens | antagonist | Link |
| target | P42081 | CD86 | T-lymphocyte activation antigen CD86 | Homo sapiens | antagonist | Link |
| target | P16410 | CTLA4 | Cytotoxic T-lymphocyte protein 4 | Homo sapiens | inhibitor | Link |